HANGZHOU TIGERMED CO. H 1 (F:5HZ1) — Stock Price
HANGZHOU TIGERMED CO. H 1 (F:5HZ1) is currently trading at €5.05 EUR, up 1.00% today. Over the past 52 weeks, shares have ranged between €3.22 and €5.85. This page tracks HANGZHOU TIGERMED CO. H 1's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market value of HANGZHOU TIGERMED CO. H 1.
HANGZHOU TIGERMED CO. H 1 (5HZ1) Stock Price Chart — Daily History & Trading Volume
The chart below tracks HANGZHOU TIGERMED CO. H 1's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
HANGZHOU TIGERMED CO. H 1 Income Statement — Revenue, Profit & Earnings by Year
HANGZHOU TIGERMED CO. H 1's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €6.83 Billion | €6.60 Billion | €7.38 Billion | €7.09 Billion | €5.21 Billion |
| Cost of Revenue | €4.96 Billion | €4.36 Billion | €4.54 Billion | €4.28 Billion | €2.94 Billion |
| Gross Profit | €1.87 Billion | €2.24 Billion | €2.85 Billion | €2.81 Billion | €2.27 Billion |
| Research & Development | €257.64 Million | €238.39 Million | €261.56 Million | €234.62 Million | €211.83 Million |
| SG&A | €322.20 Million | €349.25 Million | €306.72 Million | €292.55 Million | €279.51 Million |
| Total Operating Expenses | €6.17 Billion | €5.54 Billion | €5.63 Billion | €5.27 Billion | €3.84 Billion |
| Operating Income | €666.64 Million | €1.07 Billion | €1.76 Billion | €1.81 Billion | €1.38 Billion |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €90.56 Million | €141.24 Million | €119.90 Million | €83.18 Million | €24.91 Million |
| Income Before Tax | €1.00 Billion | €664.46 Million | €2.49 Billion | €2.59 Billion | €3.68 Billion |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €887.89 Million | €405.14 Million | €2.02 Billion | €2.01 Billion | €2.87 Billion |
HANGZHOU TIGERMED CO. H 1 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes HANGZHOU TIGERMED CO. H 1's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €28.36 Billion | €28.67 Billion | €29.68 Billion | €27.45 Billion | €23.74 Billion |
| Total Current Assets | €6.18 Billion | €6.30 Billion | €11.34 Billion | €11.11 Billion | €10.85 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €59.46 Million | €74.85 Million | €42.14 Million | €24.95 Million | €29.18 Million |
| Net Receivables | €1.41 Billion | €1.36 Billion | €1.26 Billion | €1.03 Billion | €809.13 Million |
| Inventory | €41.50 Million | €31.96 Million | €23.40 Million | €22.20 Million | €6.10 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | €3.52 Billion | €3.23 Billion | €2.76 Billion | €2.49 Billion | €1.78 Billion |
| Total Liabilities | €4.10 Billion | €4.61 Billion | €5.23 Billion | €4.77 Billion | €3.14 Billion |
| Total Current Liabilities | €2.84 Billion | €3.66 Billion | €4.14 Billion | €3.73 Billion | €2.41 Billion |
| Long-term Debt | €603.03 Million | €323.65 Million | €434.22 Million | €244.64 Million | — |
| Net Debt | — | €180.32 Million | — | — | — |
| Total Stockholder Equity | €20.96 Billion | €20.67 Billion | €21.03 Billion | €19.58 Billion | €18.12 Billion |
| Retained Earnings | €9.32 Billion | €8.69 Billion | €8.77 Billion | €7.27 Billion | €5.77 Billion |
HANGZHOU TIGERMED CO. H 1 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how HANGZHOU TIGERMED CO. H 1 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €1.12 Billion | €1.10 Billion | €1.15 Billion | €1.36 Billion | €1.42 Billion |
| Capital Expenditures | €214.37 Million | €356.55 Million | €313.76 Million | €448.60 Million | €368.62 Million |
| Free Cash Flow | €903.72 Million | €740.45 Million | €836.68 Million | €908.90 Million | €1.06 Billion |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | €-343.66 Million | €642.16 Million | €589.87 Million | €492.00 Million | €284.23 Million |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | €326.67 Million | €324.14 Million | €305.69 Million | €264.75 Million | €188.92 Million |
| Change in Cash | €-325.89 Million | €-5.35 Billion | €-382.80 Million | €-595.68 Million | €-1.58 Billion |
HANGZHOU TIGERMED CO. H 1 Earnings History — EPS Actual vs. Analyst Estimates
Track HANGZHOU TIGERMED CO. H 1's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 28, 2026 | — | — | — |
| Oct 29, 2025 | — | — | — |
| Apr 28, 2025 | — | — | — |